Sr. Director of Product at Aisera, Jigar brings 15+ years in enterprise AI, GenAI innovation, agentic automation and product-led growth. Enterprise AI is in the midst of a fundamental shift. The early ...
Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...
As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...
In education as in finance, a diverse portfolio can be the most sustainable investment. School District 11 in Colorado Springs hopes this kind of portfolio approach will enable it to continue to ...
An exhaustive cost-benefit analysis of population genetic testing published in Annals of Internal Medicine concludes with a recommendation to U.S. health policymakers to adopt routine testing of ...
Meanwhile, the economic environment is adding to the financial pressure, and employers are seeking ways to reduce costs across their businesses. As a result, employers may consider switching to a ...
CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the most ...
Lifetime treatment with statins is a cost-effective therapy across a wide range of elderly patients with and without cardiovascular disease, according to an analysis published this week in Heart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results